Trial Profile

Targeting Gut Microbiota to Improve Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms TACITO

Most Recent Events

01 Apr 2026 Primary endpoint (Number of participants who will be free from tumor progression, as assessed by RECIST criteria v. 1.1.) has not been met, based on results published in the Nature Medicine.
01 Apr 2026 Results were published in the Nature Medicine.
08 Sep 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com